Development of Population and Bayesian Models for Applied Use in Patients Receiving Cefepime.

abstract：:Sulphonylureas have remained the mainstay of oral therapy for type 2 (non-insulin-dependent) diabetes mellitus (NIDDM). They stimulate insulin release from pancreatic beta cells. Pharmacokinetic differences between the various sulphonylureas are of clinical importance in terms of the time to onset of action, timing of...

journal_title：Clinical pharmacokinetics

authors： Melander A,Donnelly R,Rydberg T

更新日期：1998-03-01 00:00:00

abstract：INTRODUCTION:The inhaled corticosteroid (ICS) fluticasone furoate is in development, in combination with the long-acting beta2-agonist vilanterol for the once-daily treatment of asthma and chronic obstructive pulmonary disease and as a monotherapy treatment for asthma. Corticosteroids, including ICSs, have the potentia...

journal_title：Clinical pharmacokinetics

authors： Allen A

更新日期：2013-10-01 00:00:00

abstract：:Ketoprofen, a potent nonsteroidal anti-inflammatory drug (NSAID) of the 2-arylpropionic acid class, has been used clinically for over 15 years in Europe, and has recently been introduced in the United States. Although it possesses a chiral centre, with only the S-enantiomer possessing beneficial pharmacological activi...

journal_title：Clinical pharmacokinetics

authors： Jamali F,Brocks DR

更新日期：1990-09-01 00:00:00

abstract：:Most of the currently available psychotropic drugs form 1 or more active metabolites during in vivo biotransformation in humans and/or animals. In some cases these metabolites are rapidly conjugated and excreted, but in others they attain blood and/or brain concentrations within the same range as, or even higher than,...

journal_title：Clinical pharmacokinetics

authors： Caccia S,Garattini S

更新日期：1990-06-01 00:00:00

abstract：:A reduction in plasma albumin concentration, as seen in patients with the nephrotic syndrome, is usually associated with a decrease in plasma protein binding of highly bound drugs. Therefore, the fraction of the unbound drug increases, but the absolute free concentration remains essentially unchanged due to a compensa...

journal_title：Clinical pharmacokinetics

authors： Gugler R,Azarnoff DL

更新日期：1976-01-01 00:00:00

abstract：:The various components required for individualising clinical drug dosage regimens are reviewed, including a study of 3 types of fitting procedures, 2 types of gentamicin pharmacokinetic model and the utility of D-optimal times for obtaining serum gentamicin concentrations. The combination of the current Bayesian fitti...

journal_title：Clinical pharmacokinetics

authors： Jelliffe RW,Iglesias T,Hurst AK,Foo KA,Rodriguez J

更新日期：1991-12-01 00:00:00

abstract：BACKGROUND:Hydroxychloroquine is an oral drug prescribed to pregnant women with rheumatic disease to reduce disease activity and prevent flares. Physiologic changes during pregnancy may substantially alter drug pharmacokinetics. However, the effect of pregnancy on hydroxychloroquine disposition and the potential need f...

journal_title：Clinical pharmacokinetics

authors： Balevic SJ,Green TP,Clowse MEB,Eudy AM,Schanberg LE,Cohen-Wolkowiez M

更新日期：2019-04-01 00:00:00

abstract：BACKGROUND:Olmesartan medoxomil (CS-866) is a new orally active angiotensin II receptor antagonist that is highly selective for the AT1 receptor subtype. OBJECTIVE:To develop a population pharmacokinetic model for olmesartan (RNH-6270), the active metabolite of olmesartan medoxomil, in healthy volunteers and hypertens...

journal_title：Clinical pharmacokinetics

authors： Yoshihara K,Gao Y,Shiga H,Wada DR,Hisaoka M

更新日期：2005-01-01 00:00:00

abstract：:The effects of liver disease on pharmacokinetics and pharmacodynamics are highly variable, and difficult to predict as the mechanisms of these effects are not well understood. Since the majority of the published literature is concerned with cirrhotic liver disease, this review also focuses mainly on this area. Four di...

journal_title：Clinical pharmacokinetics

authors： Morgan DJ,McLean AJ

更新日期：1995-11-01 00:00:00

abstract：:The ability of a new multiple-dose non-linear regression analysis program to predict steady-state aminoglycoside peak and trough serum concentrations was evaluated. 30 patients receiving either amikacin (7), gentamicin (10) or tobramycin (13) were studied. A standard method of prediction which requires the collection ...

journal_title：Clinical pharmacokinetics

authors： Koup JR,Killen T,Bauer LA

更新日期：1983-09-01 00:00:00

abstract：:Sex-related differences in the disposition of some analgesics, anxiolytics and hypnotics have recently been reported. With certain benzodiazepines, sex has been shown to be a more important determinant of variability in drug disposition than age, while with other benzodiazepines an age-related decline in clearance was...

journal_title：Clinical pharmacokinetics

authors： Wilson K

更新日期：1984-05-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Escitalopram is one of the most commonly prescribed selective serotonin reuptake inhibitors (SSRIs). It is thought to act by blocking the serotonin transporter (SERT). However, its dose-SERT occupancy relationship is not well known, so it is not clear what level of SERT blockade is achieved by ...

journal_title：Clinical pharmacokinetics

authors： Kim E,Howes OD,Kim BH,Chon MW,Seo S,Turkheimer FE,Lee JS,Lee YS,Kwon JS

更新日期：2017-04-01 00:00:00

abstract：BACKGROUND:A population pharmacokinetic (PK) protein-binding model was developed to (1) predict free mycophenolic acid (fMPA) based on total MPA (tMPA) concentrations in renal transplant patients, to establish the therapeutic range of fMPA through pharmacokinetic-pharmacodynamic studies; and (2) provide a guideline for...

journal_title：Clinical pharmacokinetics

authors： Colom H,Andreu F,van Gelder T,Hesselink DA,de Winter BCM,Bestard O,Torras J,Cruzado JM,Grinyó JM,Lloberas N

更新日期：2018-07-01 00:00:00

abstract：:Due to concern and debate in the epilepsy medical community and to the current interest of the US Food and Drug Administration (FDA) in revising approaches to the approval of generic drugs, the FDA is currently supporting ongoing bioequivalence studies of antiepileptic drugs, the EQUIGEN studies. During the design of ...

journal_title：Clinical pharmacokinetics

authors： Diaz FJ,Berg MJ,Krebill R,Welty T,Gidal BE,Alloway R,Privitera M

更新日期：2013-12-01 00:00:00

abstract：:Hydroxymetabolites of the antidepressants nortriptyline and desipramine, like the parent drugs, inhibit neuronal uptake of noradrenaline (norepinephrine). In both plasma and cerebrospinal fluid (CSF), the concentrations of the 10-hydroxymetabolites of nortriptyline (10-OH-NT) are usually higher than those of the paren...

journal_title：Clinical pharmacokinetics

authors： Nordin C,Bertilsson L

更新日期：1995-01-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:Tesamorelin is a synthetic analogue of growth hormone-releasing factor (GRF), which increases basal and pulsatile growth hormone (GH) secretion and subsequently increases insulin-like growth factor (IGF)-1. Limited information is available about the pharmacokinetics of this compound. Consequen...

journal_title：Clinical pharmacokinetics

authors： González-Sales M,Barrière O,Tremblay PO,Nekka F,Mamputu JC,Boudreault S,Tanguay M

更新日期：2015-03-01 00:00:00

abstract：:The safety profile of any pharmacological agent is defined on the basis of its toxicity, tolerability and potential for pharmacokinetic and/or pharmacodynamic interactions with other compounds, which may belong to the same or to a different pharmacological class. Drug-drug interactions are important in clinical practi...

journal_title：Clinical pharmacokinetics

authors： Negro RD

更新日期：1998-08-01 00:00:00

abstract：:The US Food and Drug Administration (FDA) draft guidance for industry on drug interaction studies recommends, but does not mandate, that both cigarette smokers and non-smokers can be used to study drug metabolism in clinical trials, and that important results related to smoking should be included in drug labelling to ...

journal_title：Clinical pharmacokinetics

authors： Li H,Shi Q

更新日期：2015-05-01 00:00:00

abstract：BACKGROUND:Duloxetine, a selective serotonin (5-hydroxytryptamine) and norepinephrine reuptake inhibitor, has been approved since 2004 for the treatment of adults with major depressive disorder (MDD). It is currently not approved for use in pediatric patients (aged <18 years) with MDD. The clinical development program ...

journal_title：Clinical pharmacokinetics

authors： Lobo ED,Quinlan T,Prakash A

更新日期：2014-08-01 00:00:00

abstract：:The intracellular pharmacokinetics of the different classes of antimicrobials into surrogate markers of tissue accumulation (alveolar macrophages and/or total alveolar cells collected by means of bronchoalveolar lavage or peripheral white blood cells) was reviewed. The aim of this review was to discuss the clinical im...

journal_title：Clinical pharmacokinetics

authors： Pea F

更新日期：2018-02-01 00:00:00

abstract：:This article reviews the information available to assist pharmacokineticists in the prediction of metabolic drug interactions. Significant advances in this area have been made in the last decade, permitting the identification in early drug development of dominant cytochrome P450 (CYP) isoform(s) metabolising a particu...

journal_title：Clinical pharmacokinetics

authors： Bertz RJ,Granneman GR

更新日期：1997-03-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:Two phase I drug interaction studies were performed with oral enzalutamide, which is approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC). METHODS:A parallel-treatment design (n = 41) was used to evaluate the effects of a strong cytochrome P450 (CYP) 2C8 inhib...

journal_title：Clinical pharmacokinetics

authors： Gibbons JA,de Vries M,Krauwinkel W,Ohtsu Y,Noukens J,van der Walt JS,Mol R,Mordenti J,Ouatas T

更新日期：2015-10-01 00:00:00

abstract：:Drug-drug, drug-formulation and drug-meal interactions are of clinical concern for orally administered drugs that possess a narrow therapeutic index. This review presents the current status of information regarding interactions which may influence the gastrointestinal (GI) absorption of orally administered drugs. Abso...

journal_title：Clinical pharmacokinetics

authors： Fleisher D,Li C,Zhou Y,Pao LH,Karim A

更新日期：1999-03-01 00:00:00

abstract：:Etodolac is a chiral nonsteroidal anti-inflammatory drug (NSAID) that is marked as the racemate. Currently, the drug is available in several countries for the treatment of arthritis and the alleviation of pain. Etodolac possesses several unique disposition features mainly due to its stereoselective pharmacokinetics. I...

journal_title：Clinical pharmacokinetics

authors： Brocks DR,Jamali F

更新日期：1994-04-01 00:00:00

abstract：:It should be recognized that children are not small adults, hence dosing in children should not be a 'small adult dose'. A mean population dose in all age groups is just an average dose and not necessarily the best or the correct dose for a given patient. The dose of a drug varies from patient to patient and individua...

journal_title：Clinical pharmacokinetics

authors： Mahmood I

更新日期：2014-04-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Daclizumab high-yield process (DAC HYP) is a humanized monoclonal antibody that selectively blocks the α-subunit (CD25) of the high-affinity interleukin-2 receptors, and has shown robust efficacy as a treatment for multiple sclerosis (MS). This work quantitatively characterized the relationship...

journal_title：Clinical pharmacokinetics

authors： Minocha M,Tran JQ,Sheridan JP,Othman AA

更新日期：2016-01-01 00:00:00

abstract：:The ability of a wide variety of anionic, cationic, and neutral drugs to bind in a reversible manner to plasma proteins has long been recognised. Non-steroidal anti-inflammatory drugs (NSAIDs) are distinguished as a class by the high degree to which they bind to plasma protein. Plasma protein binding properties are pr...

journal_title：Clinical pharmacokinetics

authors： Lin JH,Cocchetto DM,Duggan DE

更新日期：1987-06-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:Upadacitinib is a janus kinase (JAK) 1 inhibitor being developed for the treatment of rheumatoid arthritis (RA) and other inflammatory diseases. This work characterized upadacitinib population pharmacokinetics in healthy subjects and RA patients and the effects of covariates on upadacitinib ex...

journal_title：Clinical pharmacokinetics

authors： Klünder B,Mohamed MF,Othman AA

更新日期：2018-08-01 00:00:00

abstract：:Sevoflurane is a comparatively recent addition to the range of inhalational anaesthetics which has been recently released for clinical use. In comparison to older inhalational agents such as isoflurane or halothane, the most important property of sevoflurane is its low solubility in the blood. This results in a more r...

journal_title：Clinical pharmacokinetics

authors： Behne M,Wilke HJ,Harder S

更新日期：1999-01-01 00:00:00

abstract：:Esmolol is an ultra short-acting intravenous cardioselective beta-antagonist. It has an extremely short elimination half-life (mean: 9 minutes; range: 4 to 16 minutes) and a total body clearance [285 ml/min/kg (17.1 L/h/kg)] approaching 3 times cardiac output and 14 times hepatic blood flow. The alpha-distribution hal...

journal_title：Clinical pharmacokinetics

authors： Wiest D

更新日期：1995-03-01 00:00:00